Company ProfilePremium

Ambalal Sarabhai Enterprises Limited

Company Profile Analysis

Tickers: AMBALALSA.NS, 500009.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Ambalal Sarabhai Enterprises Limited - Company showcase

Year Founded & Workforce

1977

104 Employees

Ambalal Sarabhai Enterprises Limited logo

Ambalal Sarabhai Enterprises Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Ambalal Sarabhai Enterprises Limited Overview

Ambalal Sarabhai Enterprises is a small, family-controlled holding-and-operating company and one of India's oldest pharmaceutical names. Today it is a diversified micro-cap with consolidated revenue of about INR 202 crore (FY2026). It works almost entirely through subsidiaries and joint ventures across two reported segments. Pharmaceuticals (about 55% of FY2026 revenue) covers niche APIs such as Amphotericin B at Synbiotics, oncology and synthetic APIs at Asence Pharma, branded domestic formulations in oncology, fertility and women's health at Sarabhai Chemicals, effervescent and Vitamin C products, and international trading through Asence Inc. (USA). Electronics (about 45%) covers Systronics laboratory and analytical instruments and Telerad broadcast-equipment distribution. The company also holds a minority interest in the CoSara molecular-diagnostics JV with Nasdaq-listed Co-Diagnostics, which is exploring a US SPAC listing. ASE combines a legacy brand, a rebuilt balance sheet and several optionality-driven assets with thin operating margins, volatile earnings, low promoter ownership (31.35%) and no dividend.


Company's own description

In its latest Directors' Report (FY2025-26), management describes a strategy of operating through focused subsidiaries and joint ventures. It says this structure supports group operating efficiency, business development and long-term growth. The report says the group has 8 subsidiaries, 2 joint ventures and 1 associate. It highlights:

Asence Inc: (wholly owned, USA): supplies finished dosage forms and APIs to international markets. It focuses on product registrations, partnerships and niche products for regulated and semi-regulated markets.

Asence Pharma Pvt. Ltd: continued scaling up its oncology and synthetic API facility at Ranoli, Vadodara. It received the demerged Oncology and Pro-Fertility division of Sarabhai Chemicals.

Systronics (India) Ltd: operates the Systronics division, which makes and markets analytical, laboratory and test-and-measurement instruments across India, and the Telerad division, which handles broadcast equipment.

Sarabhai Chemicals (India) Pvt. Ltd: domestic branded pharmaceuticals in oncology, fertility, women's healthcare and other specialty therapies.

  • Group investments described as strengthening manufacturing capability, regulatory compliance and future growth.

The company's exchange profile describes ASE as a pharmaceutical healthcare company that, through group companies, makes and markets pharmaceutical, molecular-diagnostic and electronics products in India and abroad (Screener, citing the annual report). Groww's company summary, drawn from company disclosures, adds two points. Vovantis, described as a JV, operates a USFDA-approved plant at Ranoli focused on US and European markets. Synbiotics is a USFDA-inspected maker of the antifungal API Amphotericin B.

Business model and revenue model

DimensionCharacterisation
Legal/operating structureA listed parent with minimal standalone operations: standalone revenue of about INR 4 crore a year (Screener standalone), and standalone Q4 FY2026 revenue of INR 1.52 crore (Dion Global). Almost all revenue sits in subsidiaries.
Revenue model mixAbout 100% product sales across API, formulations, instruments and distributed broadcast equipment, plus small service/AMC income in electronics. No subscription or licensing revenue is disclosed.
Pharma modelMixed. API manufacture (B2B to formulators, India and export), contract/third-party manufacturing, branded generics sold to doctors and pharmacies in India, and trading/export through Asence Inc.
Electronics modelMixed. Own-manufactured analytical and lab instruments sold to labs, educational institutions, industry and government (Systronics), and a distribution/reseller model for broadcast and pro-AV equipment (Telerad).
Value-chain positionUpstream in pharma (fermentation-derived and synthetic APIs). Mid-stream in formulations. Downstream marketing in domestic branded products. In electronics, the company acts as both an OEM and a distributor.
Customer typesPharmaceutical formulators and hospitals (API); doctors, pharmacies and hospitals (branded formulations); international distributors (Asence Inc.); educational and research labs, QC labs and government institutions (Systronics); broadcasters and production houses (Telerad).
End-marketsAnti-infectives (antifungals), oncology, fertility/IVF, women's health, nutraceuticals (Vitamin C/effervescent), veterinary (per MarketInOut description), laboratory instrumentation, broadcast and pro-video, and molecular diagnostics through the CoSara JV.

Independent characterisation

ASE is best understood as a legacy-brand micro-conglomerate in a multi-year rebuild. The founding family has spent roughly three decades settling legacy liabilities and building new vehicles. In an interview, Mohal Sarabhai described Asence as a deliberately fresh "springboard" company. The standalone entity still carries negative reserves: net worth was INR 59.48 crore against equity capital of INR 76.63 crore, with reserves of minus INR 17.15 crore (IIFL standalone balance sheet, March 2026). Value is concentrated in the subsidiaries and in equity-accounted stakes.

The economic engine is modest. Consolidated revenue has moved within a INR 163–202 crore band since FY2021. Operating margins are mid-single-digit. FY2022 was the exception, when Amphotericin B demand during India's 2021 mucormycosis outbreak drove profit to INR 47 crore. Earnings are heavily influenced by other income and equity-accounted results. The equity story therefore rests mostly on optionality: the Ranoli oncology API plant ramp, regulated-market exports, the CoSara SPAC, and the electronics business's steady profitability.

Strategy

Stated strategy themes (FY2025-26 Directors' Report and company profile)

  1. Focused subsidiaries and JVs. Each business is run as a separate vehicle with its own focus. Management says this improves efficiency and partnering ability.

  2. Disease-based solutions. Emphasis on APIs, molecular diagnostics and niche effervescent products, with technology capabilities applied across healthcare and electronics (Groww summary of company disclosure).

  3. Regulated-market expansion. Asence pursues registrations and partnerships in regulated and semi-regulated markets. Vovantis' USFDA-approved plant targets the US and EU.

  4. Oncology API scale-up. Continued ramp of the Ranoli oncology and synthetic API facility.

  5. Domestic specialty brands. Sarabhai Chemicals focuses on oncology, fertility and women's health. The Oncology and Pro-Fertility division was demerged into Asence Pharma for sharper focus.

  6. Manufacturing and compliance investment. Group investments are framed as strengthening manufacturing capabilities and regulatory compliance.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDescriptionStatus
Pharma Committee of the board13 Aug 2025Board-level committee to oversee pharma strategy and operationsFormed
CoSara SPAC exploration5 Nov 2025Co-Dx appointed Maxim Group as exclusive adviser for a US SPAC or similar listing of CoSaraExploratory; no terms or timetable disclosed
CoSara PCR Pro regulatory/manufacturing readinessFY2025–26Co-Dx reports regulatory milestones in India for the PCR Pro instrument and manufacturing readinessIn progress; Co-Dx targeted commercialisation in 2026
Demerger of Oncology and Pro-Fertility division to Asence PharmaFY2026Internal reorganisationCompleted per FY2026 DR
Ranoli API plant scale-upOngoingVolume ramp at the oncology/synthetic API plantOngoing
Section 185 loan authorisations30 Jul 2026 (AGM)Shareholders authorised loans to three related entitiesApproved
Shareholder plant visit, RanoliRescheduled to 1 Dec 2026Investor engagement initiative; registration closes 13 Nov 2026Scheduled

Medium-term targets and guidance

Not publicly disclosed. ASE does not issue financial guidance, hold earnings calls or publish medium-term targets. No sustainability or ESG commitments with quantified targets were identified. No formal cost-reduction programme has been announced.

Products & Services

ASE does not publish a product-level catalogue with prices or launch dates in its statutory filings. The table below lists every product line identifiable from company disclosures and reputable profiles. Brand-level SKU names are not publicly disclosed in the sources reviewed.

Pharmaceuticals

Product lineEntityDescription / capabilityTarget customerYear / statusPricing model
Amphotericin B (API)SynbioticsFermentation-derived polyene antifungal API for conventional, lipid and liposomal formulations. Described as India's only Amphotericin B API manufacturer (2021 BSE filing). USFDA-inspected site.Formulators (India and export), government tenders during outbreaksLong-running; capacity ramp May 2021B2B contract/spot; not disclosed
Oncology APIsAsence PharmaHigh-potency/oncology and synthetic APIs from the Ranoli plantFormulators, regulated and semi-regulated marketsPlant commissioned June 2023; scaling up (FY2026 DR)—
Synthetic APIs (non-oncology)Asence PharmaGeneral synthetic API capacity at RanoliFormulators2023 onward—
Finished dosage forms (export)Asence Inc.Sourcing and supply of FDFs and APIs to international markets; product registrationsInternational distributors, institutional buyersOngoingTrading margin
Oncology formulations (domestic, branded)Sarabhai Chemicals → Asence Pharma (demerged division)Branded oncology products marketed to oncologistsHospitals, oncologists, pharmaciesOngoingBranded MRP; not disclosed
Fertility / Pro-fertility formulationsSarabhai Chemicals → Asence PharmaInfertility and IVF-support productsIVF clinics, gynaecologistsOngoing—
Women's healthcare / uro-gynaecSarabhai ChemicalsSpecialty women's-health formulationsGynaecologistsOngoing—
Vitamin C coated productsSarabhai M. ChemicalsCoated ascorbic acid for nutraceutical and pharma useFormulators, nutraceutical brandsSince August 2019B2B
Effervescent formulationsGroup (Vovantis/Sarabhai M.)Niche effervescent products, highlighted as a focus areaBrands, exportOngoing—
Novel drug delivery / regulated-market formulationsVovantis Laboratories (JV)USFDA-approved plant at Ranoli with focus on US and European marketsRegulated-market partnersOngoing—
Generics and veterinary productsSuvik Hitek / groupDomestic generics and veterinary productsDistributors, vetsOngoing—
Molecular diagnostics (PCR Pro instrument and tests)CoSara Diagnostics (JV)Co-Dx CoPrimer-based PCR tests and the PCR Pro point-of-care platform for India; Co-Dx reports CoSara regulatory progress and manufacturing readiness for PCR ProHospitals, labs, public-health programmes (including TB)Commercialisation targeted for 2026 per Co-Dx FY2025 results—

Electronics

Product lineDivisionDescription / capabilityTarget customerStatus
UV-Visible spectrophotometers (double beam, single beam)SystronicsImport-substitute analytical instrumentsQC labs, pharma, academia, researchLong-running
Photofluorimeters / fluorimetersSystronicsFluorescence measurement instrumentsLabs, educationLong-running
Laboratory and analytical instruments (pH meters, conductivity, colorimeters and similar)SystronicsGeneral lab instrumentation; specific models not disclosedEducational institutions, industry, government labsOngoing
Test and measuring instrumentsSystronicsElectronic T&M equipmentIndustry, educationOngoing
Broadcast, video and audio equipmentTeleradDistribution/integration of professional broadcast and pro-AV equipment; award-winning regional distributor (West) in 2025TV broadcasters, production houses, institutionsOngoing
Service / AMCSystronics, TeleradInstallation, maintenance and supportInstalled baseOngoing

Financial Narrative

Basis: Consolidated, INR crore, fiscal years ending 31 March. FY2025 and FY2026 headline lines come from the Directors' Report (FY2025-26). Other lines and years come from StockAnalysis (S&P data, converted from INR million) and Screener, cross-checked against the Directors' Report. Different providers classify income items differently, so "operating income" and "EBITDA" are shown on two bases and labelled.

Income statement

Notes:

  • Directors' Report FY2026: turnover INR 202.27 crore (FY2025: 196.19); other income 15.17 (11.38); total income 217.44 (207.57); finance cost 4.09 (4.26); depreciation 3.94 (4.01); profit before exceptional items 18.90 (11.19); PBT 19.33 (11.83); net profit 17.80 (4.93).

  • No diluted share instruments were identified. Basic and diluted EPS are equal.

Margins and growth

Revenue CAGR: FY2022–FY2026 (4 years): about 0.7%. FY2021–FY2026 (5 years, FY2021 revenue INR 163 crore per Screener): about 4.4%. Screener reports a 5-year sales CAGR of 4.35%.

Quarterly trajectory (INR crore, consolidated)

Sources: Arthneeti/Screener quarterly tables; Capital Market newswire for Q1 FY2027 (sales 43.56, OPM 10.42%, PBDT 6.03, PBT 4.68, NP 3.98).

  • Q1 FY2027 operating profit is derived as 10.42% × 43.56.

  • Q1 FY2027 other income is approximated from total income of INR 45.59 crore (Groww/Univest) minus revenue.

  • Q4 FY2026 PBT: Kotak Neo shows 5.84, Arthneeti shows 6.25. The two sources differ.

Balance sheet

Notes:

  • Total debt is derived as cash plus short-term investments plus net debt (StockAnalysis). MarketsMojo reports consolidated borrowings of INR 51.65 crore at March 2026, likely excluding lease liabilities.

  • The short-term/long-term debt split is not publicly disclosed in the sources reviewed. MarketsMojo indicates short-term borrowings roughly tripled (+200.7%) in FY2026 while long-term borrowings rose about 6%. This implies a mix shift toward working-capital lines.

Shareholders' equity (consolidated, point-in-time): about INR 140 crore (circa March 2025, Simply Wall St); INR 137.5 crore at 30 September 2025 (ScanX, company filing); about INR 158 crore at March 2026 (Screener book value of INR 20.66 per share × 7.663 crore shares).

Standalone net worth: FY2023 INR 37.84 crore; FY2024 40.29; FY2025 48.49; FY2026 59.48 (IIFL). Standalone reserves remain negative (minus INR 17.15 crore in FY2026).

Cash flow

Source: StockAnalysis (S&P). Bajaj Broking shows FY2025 OCF of minus INR 14.39 crore, a minor discrepancy in classification.

Ratios

Notes:

  • The current ratio is computed as current assets / (current assets minus working capital).

  • Net debt/EBITDA on an EBITDA basis of operating income plus D&A: FY2025 = 42.2 / (12.6 + 4.0) = 2.5x; FY2026 = 39.9 / (19.0 + 3.9) = 1.7x.

ROE: FY2026 about 12% (Screener consolidated ROE 12.4%; computed 17.80 / average equity of about 149 = 11.9%); FY2025 about 3.6% (computed). The Screener 3-year average is about 8.1%.

ROCE: FY2026 11.7% (Screener consolidated). ROIC is 3.5% on MarketInOut's TTM basis.

Debt/equity: 0.36x at both March 2025 and March 2026 (Simply Wall St 36.6%; MarketInOut/ScanX 0.36).

Cash conversion cycle: not reliably computable from the disclosures reviewed.

  • Receivable days rose from 65 to 82 (Screener, FY2025). Computed FY2026 receivable days are about 100 (55.4 / 202.3 × 365).

Commentary on trends, inflections and drivers

Revenue. Revenue is range-bound. FY2022's INR 197 crore benefited from the Amphotericin B demand spike. FY2023 fell 13.5% as that normalised. FY2024 was flat. FY2025 recovered 13% as Electronics grew and the Ranoli API plant began contributing. FY2026 grew a muted 2.6%. Growth is strongly back-end loaded each year because of Electronics' Q4 seasonality.

Gross margin. Gross margin has been notably stable at 39–41%. This suggests no structural pricing erosion, but also no mix-driven expansion yet from oncology APIs.

Operating leverage. Operating leverage is weak. SG&A rose from INR 26 crore to INR 33 crore over four years, which absorbed most of the gross-profit gains. EBITDA margin before other income bottomed at 3.5% in FY2024, when the new plant's fixed costs hit before revenue, and recovered to 5.9% in FY2026. Q1 FY2027 OPM of 10.4% is the best first quarter in the series and is a possible inflection, though one quarter is not a trend.

Earnings quality. Earnings quality is the central analytical issue. Other income (INR 15.2 crore in FY2026) was about 85% of FY2026 PBT. Screener flags other income of about INR 15.6 crore TTM and a low effective tax rate. The FY2026 tax line was minimal: PBT of INR 19.3 crore produced net profit of INR 17.8 crore, aided by deferred tax assets of INR 3.9 crore. Q1 FY2026's INR 8.22 crore profit was driven by INR 8.4 crore of other income. Q1 FY2027's 52% profit decline came mainly from a 76% fall in other income (ScanX), even as operating profit rose roughly threefold. Investors should separate core operating improvement, which is real, from the volatility of headline profit.

Balance sheet. The balance sheet is leveraged moderately but is creeping up. Net debt rose from about INR 1 crore (FY2022) to INR 40–42 crore (FY2025–26). This reflects Ranoli capex (FY2022–23 capex of INR 36 crore), a working-capital build in FY2025 (receivables jumped INR 21 crore), and lower liquid investments. FY2026 brought partial repair: positive FCF of INR 9 crore and working capital back to positive. Goodwill of INR 24.5 crore (about 15% of equity) has been stable, with one INR 0.14 crore impairment in FY2024.

Shareholder returns. No dividend has been paid in at least ten years (finanzen.ch dividend history 2017–2026 shows zero). The Directors' Report again expressed inability to recommend a dividend for FY2026. Standalone negative reserves constrain distributable profits.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentWhat it contains (entities)Products / services

Pharmaceuticals

Synbiotics Ltd.; Asence Pharma Pvt. Ltd.; Asence Inc. (USA); Sarabhai Chemicals (India) Pvt. Ltd.; Sarabhai M. Chemicals Ltd.; Suvik Hitek Pvt. Ltd.; equity-accounted Vovantis Laboratories (JV/associate status: see 4.3) and CoSara Diagnostics (JV)

Amphotericin B API; oncology and synthetic APIs; finished dosage forms for export; branded formulations (oncology, fertility, women's health); Vitamin C coated and effervescent products; molecular diagnostics through the JV

Electronics

Systronics (India) Ltd.: Systronics division and Telerad division

Spectrophotometers, fluorimeters, lab/analytical and test-and-measurement instruments; broadcast, video and audio equipment distribution

Revenue by Segment

Segment (INR Cr)FY2023FY2026

Pharmaceuticals revenue

101.37110.51

Electronics revenue

68.9191.78

Total revenue from operations

170.28202.27

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment share of revenue (%)

Segment share of revenue (%)FY2023FY2026

Pharmaceuticals share

59.554.6

Electronics share

40.545.4

Segment Result Details

Segment result (INR Cr)FY2023

Pharmaceuticals

7.34

Electronics

9.92

Total segment results

17.26

Revenue by Segment (Quarterly)

Segment (INR Cr)Q1FY2024Q1FY2026Q4FY2026Q1FY2027

Pharmaceuticals revenue

19.8325.4630.3425.26

Electronics revenue

16.2714.8735.1518.30

Total

36.1040.3465.4943.56

Results by Segment

Segment result (INR Cr)Q1FY2024Q2FY2026

Pharmaceuticals result

-4.95-1.21

Electronics result

1.302.13

Group Entities

EntityRelationshipFunctionStatus / note

Synbiotics Ltd.

Subsidiary

Amphotericin B API (fermentation); USFDA-inspected; JV partner in CoSara

Received bulk drug division 2010

Asence Inc. (USA)

Wholly owned subsidiary

International trading of FDFs and APIs

"Springboard" vehicle

Asence Pharma Pvt. Ltd.

Subsidiary

Oncology and synthetic API plant, Ranoli (commissioned June 2023); received Oncology and Pro-Fertility division

Scaling up

Sarabhai Chemicals (India) Pvt. Ltd.

Subsidiary

Domestic branded formulations

Partial demerger to Asence Pharma

Sarabhai M. Chemicals Ltd.

Wholly owned subsidiary

Vitamin C coated products (since August 2019)

—

Systronics (India) Ltd.

Subsidiary

Electronics: Systronics and Telerad divisions

Received electronics division 2010

Suvik Hitek Pvt. Ltd.

Wholly owned subsidiary

Ethical/generic products

Acquired (date n.d.)

Haryana Containers Ltd.

Subsidiary

Legacy packaging entity

Activity level not disclosed

Mautik Exim Ltd.

Subsidiary

Trading/exports

Activity level not disclosed

Vovantis Laboratories Pvt. Ltd.

JV (per Groww company summary); listed as a subsidiary in older profiles

USFDA-approved plant at Ranoli; novel drug delivery; US/EU focus

Classification discrepancy across sources

CoSara Diagnostics Pvt. Ltd.

JV (Synbiotics and Co-Diagnostics, est. 2017)

Molecular diagnostics (PCR) manufacture and sale, India first

SPAC exploration since Nov 2025

Income Statement and Per-Share Data

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Revenue from operations

196.7170.3173.6196.2202.3

Total income incl. other income (as reported)

238.8182.8183.9207.6217.4

Cost of revenue

116.4104.3102.6118.3121.4

Gross profit

81.366.771.879.081.1

SG&A

26.025.727.930.832.6

Operating income (StockAnalysis basis)

25.910.28.212.619.0

EBITDA before other income (Screener operating profit)

2586912

Interest expense

1.72.45.74.24.1

Share of profit of JVs/associates

6.4-0.7-2.70.60.4

Profit before tax (Screener)

54157519

Net profit (consolidated)

47.211.45.74.917.8

EPS basic and diluted (INR)

6.161.490.740.642.32

Dividend per share (INR)

00000

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Revenue growth YoY

19.7-13.51.913.22.6

Gross margin

41.339.241.340.340.1

Operating margin (StockAnalysis basis)

13.16.04.76.49.4

EBITDA margin before other income (Screener basis)

12.74.73.54.65.9

Net margin

24.06.73.32.58.8

Income Statement

Metric (INR Cr)Q1FY2025Q2FY2025Q3FY2025Q4FY2025Q1FY2026Q2FY2026Q3FY2026Q4FY2026Q1FY2027

Revenue from operations

40.7044.7045.9764.8140.3444.4552.0065.4943.56

Operating profit (pre-other income)

0.472.54-0.705.301.460.364.085.704.54

Other income

2.302.805.76-5.378.361.621.943.022.03

PBT

0.843.112.93-2.057.93-0.044.366.254.68

Net profit

0.352.622.23-0.278.22-0.563.646.503.98

Liquidity & Coverage Ratios

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Total assets

230.5245.7249.5271.7281.1

Cash and equivalents

12.110.110.84.96.2

Cash plus short-term investments

25.525.226.78.716.6

Total debt (derived, incl. leases)

26.745.246.150.956.5

Net debt

1.320.019.442.239.9

Goodwill

24.524.524.524.524.5

Other intangibles

0.040.020.020.011.83

Property, plant and equipment

45.464.363.062.866.2

Long-term investments

32.635.134.348.445.2

Trade and other receivables

43.930.530.151.155.4

Inventory

15.117.416.223.622.2

Total current assets

120.2110.9118.5118.6125.0

Working capital

14.78.116.2-1.926.5

Cash Flow

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

11.475.738.89-17.6213.40

Capital expenditure

15.7120.672.912.724.24

Free cash flow

-4.24-14.945.98-20.349.16

Investing cash flow

5.08-16.78-5.3013.26-10.26

Financing cash flow

-19.199.09-2.95-1.52-1.85

Dividends paid

00000

Share buybacks

00000

Cash interest paid

1.574.653.764.043.81

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROA (%)

20.54.72.31.86.3

Asset turnover (x)

0.850.690.700.720.72

Current ratio (x)

1.141.081.160.981.27

Interest coverage, operating income / interest (x)

15.54.31.43.04.7

Net debt / operating income (x)

0.051.962.383.342.10

Geography Overview

GeographyEvidenceAssessment

India (domestic)

Electronics (Systronics, Telerad) is India-focused. Sarabhai Chemicals is a domestic branded business. The CoSara initial focus is India.

Very likely the majority of revenue; exact share not publicly disclosed

United States

Asence Inc. is a US-incorporated trading subsidiary. Vovantis has a USFDA-approved plant targeting the US. Synbiotics is USFDA-inspected.

Material export channel; amount not disclosed

Europe

Vovantis targets EU markets (Groww company summary).

—

Semi-regulated markets (Africa, Asia, LatAm)

Asence registrations target semi-regulated markets (FY2026 DR).

—

“—” = not publicly disclosed.

Share Price & Returns

Reference pointPrice (INR)Source

14 May 2021 (Amphotericin rally)

40.05

Business Standard

2024 peak (52-week high reported Aug 2025)

68.0

Screener

6 May 2025

35.40

Simply Wall St

19 Dec 2025

27.91

ICICI Direct

6 Feb 2026 (52-week low INR 23.12)

25.69

Bajaj Finserv

18 Mar 2026

28.00

5paisa

21 Jul 2026

31.99

StockAnalysis

7 Aug 2026 (post-clarification spike; 52-week high about INR 50)

47.00

Google Finance

25 Sep 2026

41.09

IIFL

17 Oct 2026 (implied from INR 289.6 crore market cap)

37.8

Kotak Neo

Return (approximate, price only)

Value

—

1-year (Oct 2025 about INR 34–35 → Oct 2026 about INR 38)

about +8% to +11%

—

3-year

Not precisely verified. Simply Wall St reported +11.5% for 3 years to May 2025.

—

5-year (May 2021 about INR 40 → Oct 2026 about INR 38)

about −5%. Simply Wall St reported +107% for 5 years to May 2025, from a pre-Covid low base.

—

Valuation Multiples

MultipleASENote

Market cap (INR Cr)

about 290

Kotak Neo, 17 Oct 2026

P/E (TTM; TTM EPS about INR 1.48 after Q1 FY2027)

about 25.5

Computed: TTM net profit 13.56 crore = 17.80 − 8.22 + 3.98. Screener TTM profit INR 13.6 crore.

P/E on FY2026 EPS (INR 2.32)

about 16.3

Computed

P/B (book value INR 20.66)

about 1.83

Computed

EV (market cap + net debt INR 39.9 crore)

about 330

Computed

EV / Sales (FY2026)

about 1.63

Computed

EV / EBITDA (operating income + D&A INR 22.9 crore)

about 14.4

Computed. MarketInOut showed 10.7x at a lower price (August 2026).

Industry P/E reference

34.4

Groww "Industry P/E"

Capital Markets

ItemStatus

Analyst consensus

None. Covered by 0 analysts (Simply Wall St). MarketsMojo's automated rating has repeatedly been "Sell" (2026), later "Hold" (September 2026).

Dividend history and policy

No dividend 2017–2026 (finanzen.ch); FY2026 none recommended. No formal dividend policy disclosed.

Credit ratings (Moody's / S&P / Fitch)

None. No domestic agency rating (CRISIL/ICRA/CARE) identified in sources reviewed.

Debt maturity profile

Not publicly disclosed. Debt of about INR 51–57 crore, skewed toward short-term working-capital lines.

Equity capital changes

None. Shares outstanding constant at 76,633,296 since at least FY2017 (equity capital INR 76.63 crore).

Liquidity

Average daily volume about 176,000 shares (Google Finance, August 2026); retail-dominated

Analyst Conclusions

Management guidance and consensus

No guidance and no consensus exist. The Directors' Report frames the outlook qualitatively. It points to the subsidiary/JV strategy, the scale-up of the Ranoli oncology/API plant, international registrations through Asence, domestic specialty-brand focus and electronics continuity.

Bull case

  1. Operating inflection is underway. Consolidated OPM rose to 10.4% in Q1 FY2027 from 3.6%, and Q3–Q4 FY2026 OPMs were 7.9–8.7%. If the Ranoli plant's utilisation continues to improve, core EBITDA could more than double from FY2026's INR 12 crore (Screener basis) without heroic revenue assumptions. Gross margin is already stable at about 40%.

  2. Electronics is an under-appreciated cash generator. The segment grew about 10% CAGR to INR 91.8 crore and has stayed profitable through pharma downturns. On standalone multiples it could anchor a meaningful part of the INR 290 crore market cap.

  3. Hidden asset value and catalysts. Possible sources include a CoSara SPAC (Maxim engaged, November 2025), USFDA-approved/inspected capacity (Vovantis, Synbiotics), land held at INR 12.3 crore book (StockAnalysis), and long-term investments of INR 45 crore. At 1.8x book, any monetisation event could re-rate the stock.

Bear case

  1. Profits are not core. Other income was about 78% of FY2026 PBT. Q1 FY2027 shows how quickly reported profit falls (−52%) when one-offs disappear. On core earnings, the stock trades well above its headline P/E.

  2. Structural stagnation. Revenue CAGR was about 0.7% over four years. R&D is about 0.01% of sales. Sub-scale positions compete against far larger API and instrument companies. Three decades of "rebuild" have yet to produce a sustained growth record.

  3. Governance and partner risk. Promoter holding is 31.35% and executive control sits with the family. Shareholders approved Section 185 loans to related entities (July 2026). There has been no dividend in more than ten years. The key optionality asset (CoSara) depends on Co-Diagnostics, which reported a USD 46.9 million loss and needed a reverse split.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
~5 Nov 2026Q2 FY2027 resultsWhether OPM stays above 8% in a seasonally weak quarter; Pharma segment result turning positive
1 Dec 2026Ranoli shareholder plant visitUtilisation, customer qualifications, regulatory filings (DMFs)
Feb 2027Q3 FY2027 resultsElectronics order intake ahead of Q4
Any timeCoSara SPAC announcementDefinitive agreement, valuation, ASE/Synbiotics stake after the merger
OngoingSection 185 related-party loansAmounts disbursed and terms (quarterly RPT disclosures under Reg. 23(9))
May 2027FY2027 resultsCore EBITDA vs FY2026's INR 12 crore; other-income dependence; FCF
OngoingUSFDA inspections at Synbiotics and VovantisInspection outcomes (EIR, Form 483)
OngoingDebt trajectoryShort-term borrowings and receivable days

Analyst verdict

Ambalal Sarabhai Enterprises is a case study in legacy-brand optionality wrapped around a modest operating core. On disclosed facts, the group generates about INR 200 crore of revenue at a stable 40% gross margin. Weak scale economics convert that into only about 6% EBITDA before other income. Headline profit of INR 17.8 crore in FY2026 overstates recurring earning power, because other income contributed most of PBT. The Q1 FY2027 print showed both sides of the story. Operating margin improved sharply to 10.4%, while reported profit halved as non-operating gains disappeared.

At about INR 290 crore market cap (about 1.8x book, about 14x EV/EBITDA, about 25x trailing earnings), the market is already paying for some improvement. On the positive side, there is evidence of an operating turn. The last three reported quarters each delivered OPM above 7.8%. Electronics is a resilient, growing, profitable business. FY2026 restored positive free cash flow and working capital.

Several factors restrain conviction. Revenue has barely grown since FY2022. R&D is effectively nil. Leverage has risen. Promoter ownership is low and institutions are absent. Recent AGM approvals for related-party loans add governance noise. The most-discussed catalyst, a CoSara SPAC, depends on a financially stressed US partner and has no terms or timetable a year after it was announced.

Our synthesis is that ASE is a speculative, event-driven micro-cap rather than a compounding pharma franchise. The investment case improves materially only if three things happen together: OPM holds at or above 8–10% through a non-seasonal quarter; the Ranoli plant shows tangible regulated-market customer wins; and related-party cash flows are transparent and limited. Absent these, the stock is likely to keep trading on newsflow and liquidity spikes, as it did in August 2026, rather than on fundamentals. The Q2 FY2027 results (expected 5 November 2026) and the 1 December 2026 plant visit are the next tests.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleBoard tenureAge / DOBBackgroundSource

Kartikeya V. Sarabhai

Executive Chairman (Executive Director; Chairperson)

Director since 30 July 1992; current appointment from 1 April 2024

Born 27 Nov 1947 (age 78)

Son of Dr. Vikram Sarabhai; Chairman since mid-1990s; led liability settlement and group rebuild; retires by rotation and offered re-appointment (FY2026 AGM)

NSE governance filing, April 2026; Directors' Report

Mohal K. Sarabhai

Managing Director (KMP)

Additional Director 24 Aug 2023; MD since 21 Sep 2023

Born 5 Oct 1970 (age 56)

Long association with the company; previously CEO of several group companies (board outcome, 24 Aug 2023); architect of Asence

NSE filing; BSE filing; Simply Wall St

Ms. Chaula Shastri

Whole-time Director

On board by Nov 2019

—

Executive director (administration/communications experience per board disclosure)

BSE filing, Nov 2019; Directors' Report

Satyen R. Dave

Independent Director

From 1 April 2024

——

MarketScreener; Directors' Report

Four further Independent Directors

Independent

Mostly from the March 2024 refresh

—

Names not captured in sources reviewed

Directors' Report

Two Nominee Directors

Nominee

——

Nominating institution not disclosed in sources reviewed

Directors' Report

“—” = not publicly disclosed.

Executive Leadership Team

ExecutiveFY2020 (INR Lakh)FY2021 (INR Lakh)Note

Kartikeya V. Sarabhai

40.2541.91

Chairman & WTD remuneration (RPT disclosure, BSE, July 2021)

Mohal K. Sarabhai

52.8061.76

Shown then as "relative of director"; amounts likely paid via the group

Major Shareholders

HolderShares%

Sarabhai Holdings Pvt. Ltd. (promoter)

19,742,34825.76

Mallika Vikram Sarabhai (promoter group)

127,0730.17

Kartikeya Vikram Sarabhai

126,3460.16

Sarabhai Management Corporation Pvt. Ltd.

91,6340.12

Mohal Kartikeya Sarabhai

51,3870.07

Samvit Kartikeya Sarabhai

44,5400.06

Other promoter group entities (20 holders)

about 3.84 million

about 5.01

Total promoter and promoter group (26 holders)

24,021,492

31.35

Public (169,604 holders)

52,611,804

68.65

Shareholding Pattern

Category trend (%)Jun2022Mar2023Mar2024

Promoters

30.7630.7730.77

Institutions

0.010.010.01

Bodies corporate

2.561.675.81

Individuals

62.2361.6457.92

NRIs

1.631.731.49

Competitive Landscape

Competitors by Segment

Segment / nicheCompetitorTypeRelative positioning vs ASE

Amphotericin B (API and formulations)

—

API

Synbiotics' claim to be India's only Amphotericin B API maker gives domestic supply-security value

Amphotericin B formulations (India)

Bharat Serums & Vaccines; Sun Pharma; Cipla and other licensees of liposomal/lipid formulations

Formulators (customers and competitors)

ASE is mainly a supplier upstream of these players

Oncology APIs

MSN Laboratories, Hetero, Natco Pharma, Shilpa Medicare, Laurus Labs (oncology APIs)

API manufacturers

Vastly larger scale, regulatory filings and DMF libraries; Asence is a new entrant

Domestic oncology brands

Natco, Intas, Dr. Reddy's, Zydus, Cipla

Branded generics

Sarabhai Chemicals is a small niche player

Fertility / IVF products

Sun Pharma, Bharat Serums & Vaccines, Ferring (India), Intas

Branded

Niche share

Vitamin C / effervescent

Various nutraceutical CMOs

Contract manufacturers

Niche

Small-cap pharma peers (valuation benchmarks)

Balaxi Pharmaceuticals; Alpa Laboratories

Listed micro/small caps

Used by Tijori as benchmark peers. Five-year average ROE: ASE 19.1%, Balaxi 27.3%, Alpa 8.1% (Tijori).

Analytical / lab instruments (India)

Shimadzu, Thermo Fisher Scientific, Agilent, PerkinElmer/Revvity (premium); Labindia, Electronics India, Elico and other domestic makers (value)

Instruments

Systronics competes in the value/education segment with import-substitute products

Broadcast equipment distribution

Other authorised broadcast distributors and system integrators

Distribution

Telerad recognised as a leading regional distributor (West, 2025)

Molecular diagnostics (CoSara)

Molbio Diagnostics (Truenat), Mylab Discovery, Roche, Abbott, Cepheid

Diagnostics

CoSara is pre-scale; Molbio dominates India point-of-care PCR for TB

Healthcare micro-cap comparables (market cap)

Asarfi Hospital (about INR 393 crore market cap); QMS Medical Allied Services

Listed peers

Univest comparison: ASE market cap about INR 316 crore

Peer Comparison FY2026

MetricASE FY2026Note

Revenue (INR Cr)

202.3

Large oncology API peers report multi-thousand-crore revenue

Revenue growth (%)

2.6

Below Indian pharma sector growth (typically high single to low double digits)

EBITDA margin before other income (%)

5.9

Well below the typical 15–25% for scaled Indian API/formulation companies

R&D intensity (%)

about 0.01

Scaled Indian pharma typically spends 5–9%

Net margin (%)

8.8

Boosted by other income

Company Snapshot

$23.4M

Revenue

104

Employees

1977

Founded

Ahmedabad, India

Headquarters

SWOT Analysis

Strengths

  • Unique API capability. Synbiotics described itself as India's only Amphotericin B API manufacturer (BSE filing, May 2021). That capability helped drive FY2022 net profit of INR 47.2 crore.
  • Regulatory credentials. Synbiotics is USFDA-inspected and Vovantis operates a USFDA-approved plant at Ranoli (company profile).
  • Profitable, growing Electronics segment. Revenue rose from INR 68.9 crore (FY2023) to INR 91.8 crore (FY2026), about 10% CAGR. The segment stayed profitable with a positive INR 2.13 crore result even in Q2 FY2026, when Pharma lost money.
  • Stable gross margin. Gross margin held at 39–41% across FY2022–FY2026 (StockAnalysis), indicating pricing resilience.
  • Improved leverage and liquidity in FY2026. FCF was +INR 9.2 crore against −INR 20.3 crore in FY2025. Working capital moved to +INR 26.5 crore from −INR 1.9 crore. The current ratio improved to 1.27x.
  • Strategic optionality. The CoSara JV is the subject of a Maxim-led US SPAC exploration (Co-Dx, 5 November 2025). Asence Pharma has new oncology API capacity.

Weaknesses

  • Earnings quality. Other income of INR 15.17 crore was about 78% of FY2026 PBT of INR 19.33 crore (Directors' Report). Q1 FY2027 profit fell 52% because other income fell 76%.
  • Thin core margins. EBITDA margin before other income was 3.5–5.9% in FY2024–FY2026 (Screener basis).
  • Stagnant top line. Revenue CAGR was about 0.7% over FY2022–FY2026 and about 4.4% over five years.
  • No R&D investment of note. R&D is about 0.01% of sales (Tijori), and no patents were identified.
  • Working-capital intensity. Receivables rose from INR 30.1 crore (FY2024) to INR 55.4 crore (FY2026). Receivable days are about 100.
  • Standalone negative reserves. Standalone reserves were minus INR 17.15 crore at March 2026 (IIFL). No dividend has been paid in more than a decade.

Opportunities

  • Ranoli oncology API ramp. The plant was commissioned in June 2023 and is still scaling up (FY2026 DR). Better utilisation would bring operating leverage.
  • Regulated-market exports. Asence Inc. registrations and Vovantis' USFDA plant target the US and EU (FY2026 DR, Groww).
  • CoSara monetisation. A SPAC or US listing could crystallise value for the stake held through Synbiotics.
  • Supply-chain diversification away from China. This could benefit Indian API makers. It is an industry theme, not ASE-specific evidence.
  • Domestic instrument procurement preference. Public-procurement rules favour local manufacturing, which could help Systronics' import-substitute instruments.
  • Q1 FY2027 margin inflection. OPM was 10.4% vs 3.6% (Capital Market). If it is sustained, FY2027 core EBITDA could step up.

Threats

  • Partner fragility. Co-Diagnostics' FY2025 revenue fell to USD 0.6 million with a net loss of USD 46.9 million, and it needed a 1-for-30 reverse split (effective 1 January 2026). This threatens CoSara's funding and execution.
  • Episodic API demand. Revenue fell 13.5% in FY2023 after the Amphotericin B surge normalised.
  • API price competition, including from China, in oncology and synthetic APIs. This is an industry risk.
  • Related-party exposure. The AGM of 30 July 2026 authorised Section 185 loans to three related entities, a cash-leakage and governance risk.
  • Rising short-term borrowings. These rose about 201% YoY in FY2026 (MarketsMojo). Interest coverage was only 1.4x in FY2024.
  • Share-price volatility and speculative trading. The exchange sought a clarification in August 2026. The 52-week range is INR 23–50. Institutional ownership is nil.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr–May 2025FY2025 results: revenue INR 196.2 crore (+13%); net profit INR 4.93 crore; Q4 FY2025 net loss INR 0.27 croreWeak profit despite revenue recovery; other income turned negative in Q4
6 May 2025Share price about INR 35.4; down about 18% over one yearPost-2024 de-rating
1 Jul 2025Trading window closed ahead of Q1Routine
Jul–Aug 2025FY2025 annual report and 47th AGM cycleRoutine
4 Aug 2025Board meeting intimation for Q1 FY2026Routine
13 Aug 2025Q1 FY2026: revenue INR 40.34 crore (-0.9%); net profit INR 8.22 crore (+2,270%, driven by other income); Pharma Committee formedProfit spike driven by non-operating items; governance initiative
Aug 2025Q1 segment split: Pharma INR 25.46 crore, Electronics INR 14.87 crorePharma-led quarter
2025 (Broadcast India Show, Mumbai)Telerad (Systronics) named Best Regional Distributor – Broadcast – WestValidates electronics distribution franchise
5 Nov 2025Co-Diagnostics engages Maxim Group to pursue a SPAC transaction for CoSara DiagnosticsPotential value-unlocking catalyst for ASE's JV stake
6 Nov 2025Indian press covers the CoSara SPAC explorationRaised market awareness
13 Nov 2025Q2 FY2026: revenue INR 44.45 crore (-0.6%); net loss INR 0.56 crore; Electronics result +INR 2.13 crore; Pharma result −INR 1.21 crore; H1 net profit INR 7.66 crore; equity INR 137.5 crorePharma loss-making again
Nov 2025Co-Dx raises USD 10.8 million in two direct offeringsPartner liquidity; relevant to CoSara funding
Dec 2025Share price about INR 28–31; down 45–55% over one year (ICICI Direct, Kotak)Deep drawdown
1–2 Jan 2026Co-Dx 1-for-30 reverse stock split takes effect on NasdaqPartner listing-compliance step
4 Feb 2026Board meeting intimation for Q3Routine
6 Feb 2026Share price INR 25.69; 52-week low INR 23.12Cycle low
12 Feb 2026Q3 FY2026: revenue INR 52.00 crore (+13%); net profit INR 3.64 crore (+63% YoY)Operating recovery begins
30 Mar 2026Trading window closureRoutine
30–31 Mar 2026Co-Dx FY2025 results: revenue USD 0.6 million; net loss USD 46.9 million incl. impairment; CoSara PCR Pro regulatory milestones in India; commercialisation targeted for 2026Partner financially strained, but CoSara progressing
Apr 2026NSE integrated governance filing; NSE trading record from 20 April 2026 per one providerExpanded investor access
14 May 2026Board meeting intimation for FY2026 resultsRoutine
21 May 2026FY2026 results: revenue INR 202.3 crore (+3%); net profit INR 17.80 crore (+261%); Q4 net profit INR 6.50 crore against a loss; segment revenue Pharma INR 110.5 crore, Electronics INR 91.8 crore; internal auditor re-appointedBest profit since FY2022
21 May 2026Standalone Q4 net profit INR 2.65 crore against a loss of INR 4.96 croreParent-level improvement, driven by other income
23 May 2026AGM date set for 30 July 2026Routine
29 Jun 2026Trading window closureRoutine
7–8 Jul 2026FY2026 annual report (48th) filed under Regulation 34(1)Primary disclosure
30 Jul 202648th AGM: 9 resolutions passed, including K.V. Sarabhai re-appointment and Section 185 loans to three related entitiesRelated-party lending authority, a governance monitorable
5 Aug 2026Exchange seeks clarification on significant price movement. The stock rose from about INR 32 (late July) to INR 47 (7 August).Speculative interest
6 Aug 2026Company clarifies no undisclosed price-sensitive information; issues "Plant Visit Updates"Standard response
12 Aug 2026Q1 FY2027: sales INR 43.56 crore (+8%); OPM 10.4% (vs 3.6%); PBT INR 4.68 crore (-41%); net profit INR 3.98 crore (-52%); other income down 76%Core improvement masked by base effect
13–14 Aug 2026Quarterly snapshot and newspaper publication of resultsRoutine
Sep 2026Ranoli shareholder plant visit rescheduled to 1 December 2026Investor engagement
17 Oct 2026Market capitalisation about INR 289.6 crore (about INR 37.8 per share)Retraced from August high
Upcoming: 5 Nov 2026 (expected)Q2 FY2027 results (finanzen.ch calendar)Next catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 1,967 Mn in FY2022 to INR 2,023 Mn in FY2026.
Ambalal Sarabhai Enterprises Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations1,9671,7031,7361,9622,023
Cost of revenue1,1641,0431,0261,1831,214
Gross profit813667718790811

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Ambalal Sarabhai Enterprises, 48th Annual Report / Directors' Report FY2025-26 (via IIFL, Goodreturns) — Consolidated headline P&L, strategy, subsidiaries, board composition
  2. BSE filing: Q1 FY2027 results with segment annexure (bseindia.com corpfiling 59a141c4…) — FY2026 and Q1 FY2027 segment revenue
  3. BSE filing: Q1 FY2024 results with segment annexure (7846ff30…) — FY2023 segment revenue and results
  4. BSE filings: board outcomes 24 Aug 2023, 29 Mar 2024, 11 Aug 2021; directorate change 30 Nov 2019; RPT disclosure 3 Jul 2021 — Governance history, compensation
  5. NSE integrated governance filing (April 2026) — Director DOBs, appointment dates
  6. Shareholding pattern 31 Dec 2025 (Emkay Global reproduction) — Ownership
  7. Co-Diagnostics press release, 5 Nov 2025 (PR Newswire/BioSpace/Finviz); Co-Dx 8-K exhibit (SEC); Co-Dx FY2025 results coverage — CoSara JV and SPAC
  8. Business Standard, May 2021 — Amphotericin B, 2021 rally
  9. Capital Market newswire (JM Financial, HDFC Sec) — Quarterly results
  10. StockAnalysis.com (S&P Global data) — 5-year P&L, balance sheet, cash flow
  11. Screener.in; Arthneeti; Tapetide — Quarterly and annual series, ratios, announcements
  12. IIFL company summary and balance sheet; Goodreturns/Capitaline history — History, standalone balance sheet
  13. ScanX; Groww; Kotak Neo; Univest; MarketsMojo; MarketInOut; Simply Wall St; Tijori Finance; Equitymaster; finanzen.ch; 5paisa; ICICI Direct; Bajaj Finserv; Google Finance; GB Reports — Market data, news summaries, peer benchmarks, management interview

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.